NCT06965114View on ClinicalTrials.gov

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 27, 2026

Primary Completion Date

March 1, 2030

Study Completion Date

March 1, 2030

Conditions
Hairy Cell LeukemiaRecurrent Hairy Cell LeukemiaRefractory Hairy Cell Leukemia
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample and buccal swab collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow biopsy and aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy and aspiration

DRUG

Cladribine

Given IV

PROCEDURE

Computed Tomography

Undergo CT

BIOLOGICAL

Rituximab

Given IV

DRUG

Tovorafenib

Given PO

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center LAO, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH